STOUGHTON, Mass., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), today announced the closing of its inaugural syndicated credit facility.

Shares of Collegium Pharmaceutical, Inc. (NASDAQ: COLL - Get Free Report) reached a new 52-week high on Friday. The stock traded as high as $50.00 and last traded at $49.9750, with a volume of 203913 shares. The stock had previously closed at $49.58. Analyst Ratings Changes Several research firms have commented on COLL. Barclays initiated

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Assenagon Asset Management S.A. raised its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ: COLL) by 90.5% during the third quarter, according to its most recent filing with the SEC. The firm owned 195,589 shares of the specialty pharmaceutical company's stock after purchasing an additional 92,898 shares during the period. Assenagon Asset Management

KE, COLL and JRVR made it to the Zacks Rank #1 (Strong Buy) value stocks list on Dec. 18, 2025.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Collegium Pharmaceutical (COLL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Ensign Peak Advisors Inc cut its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ: COLL) by 18.9% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 17,793 shares of the specialty pharmaceutical company's stock after selling 4,150 shares during the

Ballast Asset Management LP bought a new stake in Collegium Pharmaceutical, Inc. (NASDAQ: COLL) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 87,206 shares of the specialty pharmaceutical company's stock, valued at approximately $2,579,000. Ballast Asset Management LP owned

Advantage Alpha Capital Partners LP decreased its stake in Collegium Pharmaceutical, Inc. (NASDAQ: COLL) by 18.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 15,531 shares of the specialty pharmaceutical company's stock after selling 3,630 shares during the quarter. Advantage Alpha Capital